On 26–27 May 2026, the global cannabis industry will gather in London for Cannabis Europa — the first major international conference since that order was signed.
It is the room where what U.S. rescheduling actually means for European operators, investors and policymakers will be debated, dissected and decided.
Europe’s medical cannabis market is now valued at over US $1.8 billion and growing fast. As Schedule III reshapes the U.S. landscape — opening new research pathways, restructuring tax treatment and unlocking institutional capital — the question for the industry on both sides of the Atlantic is no longer if the markets converge, but how.
Use code SCHEDULE3BB at checkout for 20% OFF General or VIP tickets.
Why Europe? Why Now?
With Schedule III reform underway in the U.S., North American companies have a narrow window to position themselves in Europe before the next phase of consolidation. Cannabis Europa is where those moves are made.
$1.8BN Market Size
Europe’s legal medical cannabis market — and one of the world’s fastest-growing.
1500+ Decision Makers
Operators, investors, regulators and policymakers from across Europe, the U.S., Canada & 40+ other countries
70+ Expert Speakers
Including U.S. policy insiders, European operators and global capital allocators.
2 Days Of Dealmaking
Curated networking, M&A discussions, and direct access to Europe’s top buyers.
M&A and capital flows. European valuations are evolving fast as institutional capital returns to the sector. Schedule III is rewriting the U.S. tax picture; cross-border deal activity is the natural consequence.
Distribution & supply chains. Europe’s import-led market needs reliable, EU-GMP-grade product. North American producers with the right credentials are well-positioned to participate.
Regulatory convergence. As the U.S. federal framework matures, alignment (and divergence) with European medical regimes will define which businesses scale internationally.
The room itself. Few rooms outside North America bring this density of European operators, regulators and capital into one place. For U.S. and Canadian companies, two days at the Barbican replaces months of cold outreach.
Two Cannabis Cannabis Europe Sessions You Can’t Afford To Miss
The main stage hosts two of the most consequential discussions on U.S. cannabis reform happening anywhere in 2026.
1. The View from the Whitehouse: Rescheduling in the U.S.
An unfiltered fireside on what rescheduling actually changes — and what it doesn’t. How much depends on the White House, how much sits with the DEA and the courts, and what continued uncertainty means for investors and operators watching from abroad.
Speakers
Saphira Galoob — US Cannabis Roundtable
Bryan Lanza — Former Trump Transition Team
2. Schedule III and Beyond: What a Maturing U.S. Framework Means for Europe
Rescheduling formally recognizes cannabis’s medical value under U.S. federal law for the first time, opening new research pathways and restructuring the tax environment. This panel asks what that process looks like from a European perspective — and what genuine regulatory convergence (or divergence) means for businesses operating across borders.
Speakers
David Ruskin — Kilpatrick Townsend & Stockton
Additional speakers to be announced
Use code SCHEDULE3BB at checkout for 20% OFF General or VIP tickets.
